Cytosorbents Corporation (CTSO)

Cytosorbents Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	15.62	23.83	53.83	71.42	12.23
Cash & Cash Equivalents	15.62	23.83	53.83	71.42	12.23
Cash Growth	-34.48%	-55.72%	-24.64%	483.87%	-45.31%
Receivables	6.06	5.66	4.52	5.16	4.47
Inventory	3.68	3.46	4.77	2.67	2.11
Other Current Assets	0.35	0.8	1.18	3.2	2.09
Total Current Assets	25.7	33.76	64.3	82.45	20.9
Property, Plant & Equipment	22.12	23.35	18.57	3.15	3
Other Long-Term Assets	5.44	6.12	6.65	4.35	3.48
Total Long-Term Assets	27.56	29.47	25.22	7.5	6.48
Total Assets	53.26	63.23	89.52	89.95	27.38
Accounts Payable	3.8	1.66	2.81	1.84	2.04
Current Debt	2.5	0	0	0	1.67
Other Current Liabilities	8.24	8.06	10.88	8.32	6.23
Total Current Liabilities	14.55	9.71	13.69	10.15	9.94
Long-Term Debt	15.44	18.14	13.25	0.58	14.03
Total Long-Term Liabilities	15.44	18.14	13.25	0.58	14.03
Total Liabilities	29.99	27.86	26.94	10.73	23.96
Total Debt	17.94	18.14	13.25	0.58	15.69
Debt Growth	-1.12%	36.91%	2178.21%	-96.29%	42.53%
Retained Earnings	-282.51	-254	-221.19	-196.63	-188.79
Comprehensive Income	0.53	2.33	0.53	-1.73	0.53
Shareholders' Equity	23.28	35.37	62.58	79.22	3.42
Net Cash / Debt	-2.32	5.69	40.57	70.84	-3.46
Net Cash / Debt Growth	-	-85.98%	-42.72%	-	-
Net Cash Per Share	-0.05	0.13	0.94	1.82	-0.11
Working Capital	11.16	24.05	50.61	72.3	10.97
Book Value Per Share	0.52	0.81	1.44	2.04	0.11

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).